血管非炎性蛋白1(VNN1)檢測(cè)試劑盒(酶聯(lián)免疫吸附試驗(yàn)法)
ELISA Kit for Vanin 1 (VNN1)
Pantetheinase; Pantetheine hydrolase; Tiff66; Vascular non-inflammatory molecule 1
- 編號(hào)SEC598Mu
- 物種Mus musculus (Mouse，小鼠) 相同的名稱，不同的物種。
- 實(shí)驗(yàn)方法雙抗夾心
- 反應(yīng)時(shí)長(zhǎng)3h
- 檢測(cè)范圍0.156-10ng/mL
- 靈敏度最小可檢測(cè)劑量小于等于0.060ng/mL.
- 樣本類型serum, plasma, tissue homogenates and other biological fluids
- 下載 英文說明書 中文說明書
- 規(guī)格 48T96T 96T*5 96T*10 96T*100
- 價(jià)格 ¥ 3024 ¥ 4320 ¥ 19440 ¥ 36720 ¥ 302400
- 欲了解實(shí)際交易價(jià)格和更多情況，請(qǐng)與當(dāng)?shù)亟?jīng)銷商聯(lián)系!
-
產(chǎn)品包裝(模擬)
-
產(chǎn)品包裝(模擬)
-
實(shí)驗(yàn)結(jié)果圖
-
標(biāo)準(zhǔn)曲線圖
-
通過ISO 9001、ISO 13485質(zhì)量體系認(rèn)證
特異性
本試劑盒用于檢測(cè)血管非炎性蛋白1(VNN1)，經(jīng)檢測(cè)與其它相似物質(zhì)無明顯交叉反應(yīng)。
由于受到技術(shù)及樣本來源的限制，不可能完成對(duì)所有相關(guān)或相似物質(zhì)交叉反應(yīng)檢測(cè)，因此本試劑盒有可能與未經(jīng)檢測(cè)的其它物質(zhì)有交叉反應(yīng)。
回收率
分別于定值血清及血漿樣本中加入一定量的血管非炎性蛋白1(VNN1)（加標(biāo)樣品），重復(fù)測(cè)定并計(jì)算其均值，回收率為測(cè)定值與理論值的比率。
| 樣本 | 回收率范圍(%) | 平均回收率(%) |
| serum(n=5) | 79-101 | 96 |
| EDTA plasma(n=5) | 93-105 | 98 |
| heparin plasma(n=5) | 84-98 | 95 |
精密度
精密度用樣品測(cè)定值的變異系數(shù)CV表示。CV(%) = SD/mean×100
批內(nèi)差：取同批次試劑盒對(duì)低、中、高值定值樣本進(jìn)行定量檢測(cè),每份樣本連續(xù)測(cè)定20 次，分別計(jì)算不同濃度樣本的平均值及SD值。
批間差：選取3個(gè)不同批次的試劑盒分別對(duì)低、中、高值定值樣本進(jìn)行定量測(cè)定，每個(gè)樣本使用同一試劑盒重復(fù)測(cè)定8次，分別計(jì)算不同濃度樣本的平均值及SD值。
批內(nèi)差： CV<10%
批間差： CV<12%
線性
在定值血清及血漿樣本內(nèi)加入適量的血管非炎性蛋白1(VNN1)，并倍比稀釋成1:2，1:4，1:8，1:16的待測(cè)樣本，線性范圍即為稀釋后樣本中血管非炎性蛋白1(VNN1)含量的測(cè)定值與理論值的比率。
| 樣本 | 1:2 | 1:4 | 1:8 | 1:16 |
| serum(n=5) | 85-92% | 98-105% | 85-99% | 94-101% |
| EDTA plasma(n=5) | 97-105% | 87-95% | 81-89% | 83-99% |
| heparin plasma(n=5) | 90-102% | 79-95% | 85-101% | 79-102% |
穩(wěn)定性
經(jīng)測(cè)定，試劑盒在有效期內(nèi)按推薦溫度保存，其活性降低率小于5%。
為減小外部因素對(duì)試劑盒破壞前后檢測(cè)值的影響，實(shí)驗(yàn)室的環(huán)境條件需盡量保持一致，尤其是實(shí)驗(yàn)室內(nèi)溫度、濕度及溫育條件。其次由同一實(shí)驗(yàn)員來進(jìn)行操作可減少人為誤差。
實(shí)驗(yàn)流程
1. 實(shí)驗(yàn)前標(biāo)準(zhǔn)品、試劑及樣本的準(zhǔn)備；
2. 加樣（標(biāo)準(zhǔn)品及樣本）100µL，37°C孵育1小時(shí)；
3. 吸棄，加檢測(cè)溶液A100µL，37°C孵育1小時(shí)；
4. 洗板3次；
5. 加檢測(cè)溶液B100µL，37°C孵育30分鐘；
6. 洗板5次；
7. 加TMB底物90µL，37°C孵育10-20分鐘；
8. 加終止液50µL，立即450nm讀數(shù)。
實(shí)驗(yàn)原理
將血管非炎性蛋白1(VNN1)抗體包被于96孔微孔板中，制成固相載體，向微孔中分別加入標(biāo)準(zhǔn)品或標(biāo)本，其中的血管非炎性蛋白1(VNN1)與連接于固相載體上的抗體結(jié)合，然后加入生物素化的血管非炎性蛋白1(VNN1)抗體，將未結(jié)合的生物素化抗體洗凈后，加入HRP標(biāo)記的親和素，再次徹底洗滌后加入TMB底物顯色。TMB在過氧化物酶的催化下轉(zhuǎn)化成藍(lán)色，并在酸的作用下轉(zhuǎn)化成最終的黃色。顏色的深淺和樣品中的血管非炎性蛋白1(VNN1)呈正相關(guān)。用酶標(biāo)儀在450nm波長(zhǎng)下測(cè)定吸光度(O.D.值)，計(jì)算樣品濃度。
贈(zèng)品
增值服務(wù)
相關(guān)產(chǎn)品
| 編號(hào) | 適用物種：Mus musculus (Mouse，小鼠) | 應(yīng)用(僅供研究使用，不用于臨床診斷！) |
| RPC598Mu01 | 血管非炎性蛋白1(VNN1)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
| PAC598Mu01 | 血管非炎性蛋白1(VNN1)多克隆抗體 | WB; IHC; ICC; IP. |
| LAC598Mu71 | 血管非炎性蛋白1(VNN1)多克隆抗體(生物素標(biāo)記) | WB; IHC; ICC. |
| SEC598Mu | 血管非炎性蛋白1(VNN1)檢測(cè)試劑盒(酶聯(lián)免疫吸附試驗(yàn)法) | Enzyme-linked immunosorbent assay for Antigen Detection. |
| LMC598Mu | 血管非炎性蛋白1(VNN1)等多因子檢測(cè)試劑盒(流式熒光發(fā)光法) | FLIA Kit for Antigen Detection. |
參考文獻(xiàn)
| 雜志 | 參考文獻(xiàn) |
| Toxicology | Vanin-1; a potential biomarker for nephrotoxicant-induced renal injury [ScienceDirect: S0300483X11003234] |
| Journal of Pharmacology and Experimental Therapeutics | Urinary vanin-1 as a novel biomarker for early detection of drug-induced acute kidney injury [Aspet: 192807] |
| J Pharmacol Exp Ther | Urinary vanin-1 as a novel biomarker for early detection of drug-induced acute kidney injury. [PubMed: 22399813] |
| Journal of Applied Toxicology | Early detection of renal injury using urinary vanin-1 in rats with experimental colitis [PubMed: 23307618] |
| Iranian Journal of Health and Physical Activity | Effects of Exercise and Ferula Gummosa on Apelin of Cardiac and Kidney Tissues in L-NAME induced Hypertension in Rats [Jm.um: Source] |
| Platelets | Value of vanin-1 assessment in adult patients with primary immune thrombocytopenia [Pubmed: 23534352] |
| Journal of Applied Toxicology | Early detection of renal injury using urinary vanin-1 in rats with experimental colitis. [Pubmed: 23307618] |
| Diabetes & Vascular Disease Research | Urinary Kim-1 is a sensitive biomarker for the early stage of diabetic nephropathy in Otsuka Long-Evans Tokushima Fatty rats [Sagepub:Source] |
| Food Chem Toxicol. | The effect of activated charcoal on adenine-induced chronic renal failure in rats [Pubmed:24412558] |
| Hypertension Research | Early urinary biomarkers for renal tubular damage in spontaneously hypertensive rats on a high salt intake [PubMed: 26376947] |
| Inflammation | Citrate Attenuates Adenine-Induced Chronic Renal Failure in Rats by Modulating the Th17/Treg Cell Balance [PubMed: 26253296] |
| Toxicology | Early prediction of cisplatin-induced nephrotoxicity by urinary vanin-1 in patients with urothelial carcinoma [Pubmed:27317936] |
| J Biomed Mater Res A | Nanosized titanium dioxide resulted in the activation of TGF-β/Smads/p38MAPK pathway in renal inflammation and fibration of mice [Pubmed:26850371] |
| APMIS | Citrate attenuates vascular calcification in chronic renal failure rats. [pubmed:28332248] |
| Clin Exp Pharmacol Physiol. | Early urinary biomarkers of renal tubular damage by a high-salt intake independent of blood pressure in normotensive rats. [pubmed:29027259] |
| Cellular?Physiology and Biochemistry | Gum Acacia Improves Renal Function and Ameliorates Systemic Inflammation, Oxidative and Nitrosative Stress in Streptozotocin-Induced Diabetes in Rats?… [Pubmed:29550811] |
| International Journal of Molecular?Sciences | Vanin-1 in Renal Pelvic Urine Reflects Kidney Injury in a Rat Model of Hydronephrosis [Pubmed: 30332759] |
| International Journal of Molecular Sciences | Involvement of Vanin-1 in Ameliorating Effect of Oxidative Renal Tubular Injury in Dahl-Salt Sensitive Rats [Pubmed: 31514290] |
| The Journal of Clinical Hypertension homepage | Urinary vanin‐1 associated with chronic kidney disease in hypertensive patients: A pilot study [Pubmed: 32869948] |
| J Clin Hypertens | Association of urinary vanin?\1 with kidney function decline in hypertensive patients [34029440] |
| Plasma vanin-1 as a novel biomarker of sepsis for trauma patients: a prospective multicenter cohort study [33624223] |
